Change over period: —
NSE · GRANULES
GRANULES (I)
-12.3% from the 52-week high · +49.7% above the low
Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 3,650 full-time employees. The firm operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The firm has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The firm sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
The short version. GRANULES (I) reported revenue of ₹1,560 crore for Sep 2026, up 20.3% from a year earlier. Net profit was ₹182 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 37.39% in Sep 2026, down 1.45 points over 8 quarters.
1 · The price
How has the stock traded?
GRANULES (I) trades 12.3% below its 52-week high and 49.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,560 cr.
Sep 2026 net profit of ₹182 cr.
1.6 pts higher than a year earlier.
Revenue compounded at 6.0% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1560 | 1477 | 1471 | 1388 | 1297 | 1210 | 1197 | 1138 |
| Net profit | 182 | 180 | 202 | 150 | 131 | 113 | 152 | 118 |
| Net margin % | 11.7 | 12.2 | 13.7 | 10.8 | 10.1 | 9.3 | 12.7 | 10.3 |
| EPS (₹) | 6.67 | 7.26 | 8.13 | 6.19 | 5.38 | 4.64 | 6.27 | 4.85 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5366 | 4482 | 4506 | 4512 | 3765 | 3238 | 2599 | 2279 |
| Net profit | 595 | 502 | 405 | 517 | 413 | 549 | 335 | 236 |
| Net margin % | 11.1 | 11.2 | 9.0 | 11.4 | 11.0 | 17.0 | 12.9 | 10.4 |
| EPS (₹) | 24.01 | 20.68 | 16.72 | 21.34 | 16.64 | 22.18 | 13.19 | 9.3 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.7% in Mar 2026; debt to equity is 0.26.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.7 | 13.5 | 12.6 | 18.2 |
| Return on capital % | 16.0 | 18.0 | 19.0 | 24.0 |
| EBITDA margin % | 22.2 | 22.0 | 19.1 | 20.5 |
| Net margin % | 11.1 | 11.2 | 9.0 | 11.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 6.0% | 10.5% |
| Profit CAGR | 4.8% | 1.6% |
4 · The owners
Who holds it, and are they adding?
Down 1.45 pts over 8 quarters.
Up 4.38 pts over 8 quarters.
Down 4.24 pts over 8 quarters.
+12 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 38.84 | 38.84 | 38.82 | 38.82 | 38.82 | 38.02 | 38.01 | 37.39 | -1.45 |
| FII | 15.87 | 15.15 | 13.24 | 14.09 | 13.55 | 15.31 | 17.5 | 20.25 | +4.38 |
| DII | 19.57 | 22.45 | 23.53 | 17.92 | 17.48 | 17.01 | 16.11 | 15.33 | -4.24 |
| Public | 25.71 | 23.57 | 24.41 | 29.17 | 30.15 | 29.66 | 28.38 | 27.04 | +1.33 |
Mutual fund holdings · Oct 2026
93 schemes hold this stock
81 the month before.
- Capitalmind Flexi Cap Fund3.57% of NAV
- Old Bridge Focused Fund3.06% of NAV
- Kotak Quant Fund3.05% of NAV
- NJ Momentum Fund2.55% of NAV
- UNION ACTIVE MOMENTUM FUND2.42% of NAV
- ADITYA BIRLA SUN LIFE SMALL CAP FUND2.09% of NAV
- ADITYA BIRLA SUN LIFE MULTI-CAP FUND1.91% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND1.87% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GRANULES (I) are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about GRANULES (I)
What is the GRANULES (I) share price?
GRANULES (I) (GRANULES) last closed at ₹801.20, up 0.46% on the day. Its 52-week range is ₹532.85 to ₹909.30.
What is the market cap of GRANULES (I)?
GRANULES (I) has a market capitalisation of about ₹19,770 crore. Its price-to-earnings ratio is 28.0.
How are GRANULES (I)'s latest results?
GRANULES (I) reported revenue of ₹1,560 crore for Sep 2026, up 20.3% from a year earlier. Net profit was ₹182 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 37.39% in Sep 2026, down 1.45 points over 8 quarters.
Who owns GRANULES (I)?
As of Sep 2026, shareholding was: Promoter 37.39%, FII 20.25%, DII 15.33%, Public 27.04%.
How many mutual funds hold GRANULES (I)?
93 mutual fund schemes held GRANULES (I) in October 2026. That compares with 81 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 31 Jul 2025 · Final Dividend - Rs. 1.5
- 30 Jul 2024 · Final Dividend - Rs. 1.5
- 03 Aug 2023 · Final Dividend - Rs. 1.5
- 19 Jul 2022 · Final Dividend - Rs. 0.75
- 17 Feb 2022 · Interim Dividend - Rs. 0.25
- 24 Nov 2021 · Interim Dividend - Rs. 0.25
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.